Circulating DNA-Important Biomarker of CancerDachuan Jin1*, Suqing Xie2, Zhicheng Mo3, Yingjian Liang4 Baoqiang Guo5, Gengming Huang6 and Jianli Dong6
- *Corresponding Author:
- Dachuan Jin
Research Institute, The Methodist Hospital, Texas, USA
Tel: (832) 564-9081
E-mail: [email protected]
Received date: April 19, 2012; Accepted date: May 02, 2012; Published date: May 07, 2012
Citation: Jin D, Xie S, Mo Z, Liang Y, Guo B, et al. (2012) Circulating DNA-Important Biomarker of Cancer. J Mol Biomarkers Diagn S2:009. doi:10.4172/2155-9929.S2-009
Copyright: © 2012 Jin D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Circulating extracellular nucleic acids, especially DNA, was discovered more than sixty years ago, but it is becoming hot just in the last two decades because it is now widely recognized as a very promising biomarker for the early diagnosis, monitoring, and evaluation of prognosis of cancer. In addition, compared with traditional surgical approaches and other biochemical tests, circulating DNA as a biomarker, owns many obvious advantages. It is easily accessible, reliable, reproducible and early detectable in cancer. It is also very sensitive and specific if cancer specific DNA alterations are tested instead of elevation of circulating DNA concentration. But the clinical application of this biomarker is still just limited to obstetrics and prenatal diagnosis. This review throws light on its history, current research update and potential clinical application in cancer diagnosis and management. In addition, major detection technologies of circulating DNA are summarized concisely and comprehensively.